Citations

Clear

626 citation(s) found for "Mehta, SH".

Treatment of Involuntary Movements with Carbamazepine in Dystonic‐Choreoathetoid Cerebral Palsy
Mehta, Shyamal H. , Sawhney, I. M. S. , Yoganathan, Kathir, Trumble, Jill P., Morgan, John C. , Sethi, Kapil D.

Mayo Clinic

Movement Disorders Clinical Practice | April 11, 2014 | Volume: 1 | Issue: 1 | Pages: 82-83

10.1002/mdc3.12002 | PMID 30363927 Get It

AbstractChoreoathetoid movements are quite common in cerebral palsy (CP). This is the first report of a patient with choreoathetoid CP who was successfully treated with carbamazepine. Therefore, clinicians should try carbamazepine for involuntary movements in CP patients before pursuing other procudures.
Increasing LH Pulsatility in Women With Hypothalamic Amenorrhoea Using Intravenous Infusion of Kisspeptin-54
Jayasena, Channa , Abbara, Ali , Veldhuis, Johannes D. , Comninos, Alexander , Ratnasabapathy, Risheka , Silva, Akila De, Nijher, Gurjinder, Ganiyu‐Dada, Zainab, Mehta, Amrish, Todd, Catriona, Ghatei, Mohammad A., Bloom, Stephen R. , Dhillo, Waljit S. , Jayasena, Channa N, Jayasena, Channa N

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | February 11, 2014 | Volume: 99 | Issue: 6 | Pages: E953-E961

10.1210/jc.2013-1569 | PMID 24517142 Get It

Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH
Cairncross, J. Gregory , Wang, Meihua , Jenkins, Robert B. , Shaw, Edward G. , Brachman, David, Buckner, Jan C. , Fink, Karen, Souhami, Luís, Laperrière, Normand , Mehta, Minesh P. , Curran, Walter J. , Giannini, Caterina , Huse, Jason T. , Mehta, Minesh P

Mayo Clinic

Journal of Clinical Oncology | February 11, 2014 | Volume: 32 | Issue: 8 | Pages: 783-790

10.1200/jco.2013.49.3726 | PMID 24516018 Get It

Purpose Patients with 1p/19q codeleted anaplastic oligodendroglial tumors who participated in RTOG (Radiation Therapy Oncology Group) 9402 lived much longer after chemoradiotherapy (CRT) than radiation therapy (RT) alone. However, some patients with noncodeleted tumors also benefited from CRT; survival curves separated after the median had been reached, and significantly more patients lived ≥ 10 years after CRT than RT. Thus, 1p/19q status may not identify all responders to CRT. Patients and Methods Using trial data, we inquired whether an IDH mutation or germ-line polymorphism associated with IDH-mutant gliomas identified the patients in RTOG 9402 who benefited from CRT. Results IDH status was evaluable in 210 of 291 patients; 156 (74%) had mutations. rs55705857 was evaluable in 245 patients; 76 (31%) carried the G risk allele. Both were associated with longer progression-free survival after CRT, and mutant IDH was associated with longer overall survival (9.4 v 5.7 years; hazard ratio [HR], 0.59; 95% CI, 0.40 to 0.86; P = .006). For those with wild-type tumors, CRT did not prolong median survival (1.3 v 1.8 years; HR, 1.14; 95% CI, 0.63 to 2.04; P = .67) or 10-year survival rate (CRT, 6% v RT, 4%). Patients with codeleted mutated tumors (14.7 v 6.8 years; HR, 0.49; 95% CI, 0.28 to 0.85; P = .01) and noncodeleted mutated tumors (5.5 v 3.3 years; HR, 0.56; 95% CI, 0.32 to 0.99; P < .05) lived longer after CRT than RT. Conclusion IDH mutational status identified patients with oligodendroglial tumors who did (and did not) benefit from alkylating-agent chemotherapy with RT. Although patients with codeleted tumors lived longest, patients with noncodeleted IDH-mutated tumors also lived longer after CRT.
Effect of the Addition of Chemotherapy to Radiotherapy on Cognitive Function in Patients With Low-Grade Glioma: Secondary Analysis of RTOG 98-02
Prabhu, Roshan S. , Won, Minhee , Shaw, Edward G. , Hu, Chen , Brachman, David, Buckner, Jan C. , Stelzer, K. , Barger, Geoffrey, Brown, Paul D. , Mehta, Minesh P. , Gilbert, Mark R. , Mehta, Minesh P

Mayo Clinic

Journal of Clinical Oncology | January 14, 2014 | Volume: 32 | Issue: 6 | Pages: 535-541

10.1200/jco.2013.53.1830 | PMID 24419119 Get It

Purpose The addition of PCV (procarbazine, lomustine, and vincristine) chemotherapy to radiotherapy (RT) for patients with WHO grade 2 glioma improves progression-free survival (PFS). The effect of therapy intensification on cognitive function (CF) remains a concern in this population with substantial long-term survival. Patients and Methods A total of 251 patients with WHO grade 2 glioma age ≥ 40 years with any extent of resection or age < 40 years with subtotal resection/biopsy were randomly assigned to RT (54 Gy) or RT plus PCV. We observed 111 patients age < 40 years with gross total resection. CF was assessed by Mini–Mental State Examination (MMSE) at baseline and years 1, 2, 3, and 5. Results Overall, few patients experienced significant decline in MMSE score. There were no significant differences in the proportion of patients experiencing MMSE score decline between the randomized study arms at any time point. Both study arms experienced a significant gain in average MMSE score longitudinally over time, with no difference between arms. Conclusion The MMSE is a relatively insensitive tool, and subtle changes in CF may have been missed. However, the addition of PCV to RT did not result in significantly higher rates of MMSE score decline than RT alone through 5 years of follow-up. Patients in both randomly assigned arms experienced a statistically significant average MMSE score increase over time, with no difference between arms. The addition of PCV chemotherapy to RT improves PFS without excessive CF detriment over RT alone for patients with low-grade glioma.
Survey Finds Few Orthopedic Surgeons Know The Costs Of The Devices They Implant
Okike, Kanu , O’Toole, Robert V. , Pollak, Andrew N. , Bishop, Julius A. , McAndrew, Christopher M. , Mehta, Samir, Cross, William W., Garrigues, Grant E. , Lebrun, Christopher , Mehta, Samir, Harris, Mitchel B.

Mayo Clinic

Health Affairs | January 6, 2014 | Volume: 33 | Issue: 1 | Pages: 103-109

10.1377/hlthaff.2013.0453 | PMID 24395941 Get It

Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the E uropean U nion
Moulard, O., Mehta, Jyotsna , Fryzek, Jon P. , Olivares, Robert, Iqbal, Usman , Mesa, Ruben A.

Mayo Clinic

European Journal of Haematology | December 24, 2013 | Volume: 92 | Issue: 4 | Pages: 289-297

10.1111/ejh.12256 | PMID 24372927 Get It

Abstract Background Primary myelofibrosis ( PMF ), essential thrombocythemia ( ET ), and polycythemia vera ( PV ) are BCR ABL ‐negative myeloproliferative neoplasms ( MPN ). Published epidemiology data are scarce, and multiple sources are needed to assess the disease burden. Methods We assembled the most recent information available on the incidence and prevalence of myelofibrosis ( MF ), ET , and PV by conducting a structured and exhaustive literature review of the published peer‐reviewed literature in EMBASE and by reviewing online documentation from disease registries and relevant health registries in European countries. The search was restricted to human studies written in English or French and published between January 1, 2000, and December 6, 2012. Results Eleven articles identified from EMBASE , three online hematology or oncology registries, and two Web‐based databases or reports were used to summarize epidemiological estimates for MF , PV , and ET . The incidence rate of MF ranged from 0.1 per 100 000 per year to 1 per 100 000 per year. Among the various registries, the incidence of PV ranged from 0.4 per 100 000 per year to 2.8 per 100 000 per year, while the literature estimated the range of PV incidence to be 0.68 per 100 000 to 2.6 per 100 000 per year. The estimated incidence of ET was between 0.38 per 100 000 per year and 1.7 per 100 000 per year. While a few studies reported on the MPN s' prevalences, it is difficult to compare them as various types of prevalence were calculated (point prevalence vs. period prevalence) and standardization was made according to different populations (e.g., the world population and the European population). Conclusion There is a wide variation in both prevalence and incidence estimates observed across European data sources. Carefully designed studies, with standardized definitions of MPN s and complete ascertainment of patients including both primary and secondary MF s, should be conducted so that estimates of the population aimed to receive novel treatments for these neoplasms are better understood assist public health planning and provide valuable information about the burden of illness to policy makers, funding agencies, resource planners, healthcare insurers, and pharmaceutical manufacturers.
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Wang, Meihua , Aldape, Kenneth , Hegi, Monika E. , Jaeckle, Kurt A. , Armstrong, Terri S. , Won, Minhee , Blumenthal, Deborah T. , Mahajan, Anita , Schultz, Christopher J. , Erridge, Sara , Baumert, Brigitta G. , Hopkins, Kristen I., Tzuk-Shina, Tzahala, Brown, Paul D. , Chakravarti, Arnab , Curran, Walter J. , Mehta, Minesh P. , Chakravarti, Arnab , Gilbert, Mark R. , Stupp, Roger , Wefel, Jeffrey S. , Armstrong, Terri S , Mehta, Minesh P , Chakravarti, Arnab

Mayo Clinic

Journal of Clinical Oncology | October 7, 2013 | Volume: 31 | Issue: 32 | Pages: 4085-4091

10.1200/jco.2013.49.6968 | PMID 24101040 Get It

Purpose Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O 6 -methylguanine-DNA methyltransferase (MGMT) methylation status may be an important determinant of treatment response. Dose-dense (DD) temozolomide results in prolonged depletion of MGMT in blood mononuclear cells and possibly in tumor. This trial tested whether DD temozolomide improves overall survival (OS) or progression-free survival (PFS) in patients with newly diagnosed GBM. Patients and Methods This phase III trial enrolled patients older than age 18 years with a Karnofsky performance score of ≥ 60 with adequate tissue. Stratification included clinical factors and tumor MGMT methylation status. Patients were randomly assigned to standard temozolomide (arm 1) or DD temozolomide (arm 2) for 6 to 12 cycles. The primary end point was OS. Secondary analyses evaluated the impact of MGMT status. Results A total of 833 patients were randomly assigned to either arm 1 or arm 2 (1,173 registered). No statistically significant difference was observed between arms for median OS (16.6 v 14.9 months, respectively; hazard ratio [HR], 1.03; P = .63) or median PFS (5.5 v 6.7 months; HR, 0.87; P = .06). Efficacy did not differ by methylation status. MGMT methylation was associated with improved OS (21.2 v 14 months; HR, 1.74; P < .001), PFS (8.7 v 5.7 months; HR, 1.63; P < .001), and response (P = .012). There was increased grade ≥ 3 toxicity in arm 2 (34% v 53%; P < .001), mostly lymphopenia and fatigue. Conclusion This study did not demonstrate improved efficacy for DD temozolomide for newly diagnosed GBM, regardless of methylation status. However, it did confirm the prognostic significance of MGMT methylation. Feasibility of large-scale accrual, prospective tumor collection, and molecular stratification was demonstrated.
Matrix Assisted Laser Desorption Ionization Imaging Mass Spectrometry Workflow for Spatial Profiling Analysis of N-Linked Glycan Expression in Tissues
Powers, Thomas W. , Jones, E. Ellen , Betesh, Lucy, Romano, Patrick R., Gao, Peng , Copland, John A. , Mehta, Anand S. , Drake, Richard R.

Mayo Clinic

Analytical Chemistry | September 19, 2013 | Volume: 85 | Issue: 20 | Pages: 9799-9806

10.1021/ac402108x | PMID 24050758 Get It

Biomarkers for Acute Kidney Injury: Where Are We Today? Where Should We Go?
Chawla, Lakhmir S. , Kellum, John A. , Mehta, Ravindra L. , Lieske, John C. , Kashani, Kianoush , Koyner, Jay L. , Mehta, Ravindra L , Kellum, John A

Mayo Clinic

Clinical Chemistry | August 19, 2013 | Volume: 60 | Issue: 2 | Pages: 294-300

10.1373/clinchem.2012.201988 | PMID 23958848 Get It

Defining High-Sensitivity Cardiac Troponin Concentrations in the Community
Heublein, Denise M., Scott, Christopher G. , Gantzer, Mary Lou, Mehta, Ramila A. , Rodeheffer, Richard J. , Redfield, Margaret M. , Burnett, John C. , Jaffe, Allan S. , McKie, Paul M. , Jaffe, Allan S. , Scott, Christopher

Mayo Clinic

Clinical Chemistry | April 17, 2013 | Volume: 59 | Issue: 7 | Pages: 1099-1107

10.1373/clinchem.2012.198614 | PMID 23592511 Get It

BACKGROUND High-sensitivity cardiac troponin (hs-cTn) assays are now available that can detect measurable troponin in significantly more individuals in the general population than conventional assays. The clinical use of these hs-cTn assays depends on the development of proper reference values. Therefore, our objective was to define hs-cTnI reference values and determinants in the general community, in a healthy reference cohort, and in subsets with diseases. MATERIALS AND METHODS A well-characterized community-based cohort of 2042 study participants underwent clinical assessment and echocardiographic evaluation. Baseline hs-cTnI measurements were obtained in 1843 individuals. A healthy reference cohort (n = 565) without cardiac, renal, or echocardiographic abnormalities was identified. RESULTS Measurable hs-cTnI was identified in 1716 (93%) of the community-based study cohort and 499 (88%) of the healthy reference cohort. Parameters that significantly contributed to higher hs-cTnI concentrations in the healthy reference cohort included age, male sex, systolic blood pressure, and left ventricular mass. Glomerular filtration rate and body mass index were not independently associated with hs-cTnI in the healthy reference cohort. Individuals with diastolic and systolic dysfunction, hypertension, and coronary artery disease (but not impaired renal function) had significantly higher hs-cTnI values than the healthy reference cohort. CONCLUSIONS We assessed an hs-cTnI assay with the aid of echocardiographic imaging in a large, well-characterized community-based cohort. hs-cTnI is remarkably sensitive in the general population, and there are important sex and age differences among healthy reference individuals. These results have important implications for defining hs-cTnI reference values and identifying disease.